New competing products are launching in the weight-loss market, intensifying the competition between Eli Lilly and its rivals.
1 report, 1 independent
Updated Aug 11
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
New competing products are launching in the weight-loss market, intensifying the competition between Eli Lilly and its rivals.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.Also in this story
- Eli Lilly and Novo Nordisk are now competing in the basal insulin market segment.
- Eli Lilly and Novo Nordisk are facing market share losses in the GLP-1 sector, with trading taking place in Copenhagen's capital market.
- Novo Nordisk expanded its pediatric label franchise on September 15, 2026.
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
Related events
- Eli Lilly's tirzepatide proved more effective than Novo Nordisk's semaglutide in the obesity drug market.
- AbbVie and Eli Lilly are competing in the pharmaceutical market.
- Major pharmaceutical companies, including Viking Therapeutics, Eli Lilly, and Novo Nordisk, are advancing their weight loss drug pipelines.
- AbbVie, Eli Lilly, and Merck are broadening their therapeutic reach.
- Cantor Fitzgerald increased its price target on Eli Lilly and Company stock.